Ignite Creation Date:
2025-12-25 @ 12:07 AM
Ignite Modification Date:
2026-03-08 @ 11:01 PM
Study NCT ID:
NCT03393858
Status:
TERMINATED
Last Update Posted:
2024-02-07
First Post:
2018-01-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Sponsor:
Capital Medical University
Organization:
Study Overview
Official Title:
A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant Mesothelioma
Status:
TERMINATED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The number of enrolled cases is insufficient
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy combined with hyperthermia in advanced malignant mesothelioma patients.Furthermore,to characterize response to therapy,the investigators intent to explore the predictive biomarker for this regimen.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: